1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one

• ChemBase编号: 155624
• 分子式: C27H30N4O
• 平均质量: 426.5533
• 单一同位素质量: 426.2419616
• SMILES: c1ccc(cc1)C(c1ccccc1)N1CCN(CC1)CCCn1c2ccccc2[nH]c1=O
• Canonical SMILES: O=c1[nH]c2c(n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)cccc2
• InChI: InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
• InChIKey: BAINIUMDFURPJM-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
• IUPAC传统名: 1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-2,3-dihydro-1H-1,3-benzodiazol-2-one; oxatomide
• 别名: R-35443; Celtect; Cobiona; Dasten; Tinset; Oxatomide; Oxatimide; Cenacert; Fensedyl; Truxa; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; Oxatomide; 1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2h-benzimidazol-2-one

登记号

• CAS号: 60607-34-3
• EC号: 262-320-9
• MDL号: MFCD00211147
• PubChem SID: 162249762; 24278615
• PubChem CID: 4615

理论计算性质

• Acid pKa: 12.915181
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 1.8965536
• LogD (pH = 7.4): 3.6679204
• Log P: 4.624846
• 摩尔折射率: 130.9407 cm^3
• 极化性: 50.04133 Å^3
• 极化表面积: 38.82 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: DMSO; DMSO: soluble; ethanol: soluble; Methanol
• 外观: Off-White Solid; white
• 熔点: 100-115°C

安全信息

• 保存条件: Refrigerator
• RTECS编号: DE2276000
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 22
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves

药理学性质

• 相关基因信息: human ... DRD3(1814)
• 生物活性机理: Also a mediator release inhibitor via Ca influx inhibition mechanism; Histamine H 1 receptor antagonist

产品相关信息

• 纯度: ≥99%; 97%
• 应用领域: Antiasthmatic; Antihistamine agent
• Empirical Formula (Hill Notation): C27H30N4O

详细说明

Sigma Aldrich - O9387

Biochem/physiol Actions
Oxatomide is an anti-allergy compound, H1 receptor antagonist. Oxatomide suppresses PAF-induced bronchoconstriction; inhibits leukotriene production.

Toronto Research Chemicals - O845100

Orally active anti-allergic agent; related structurally to cinnarizine and having a novel biphasic mode of action.

参考文献

• Richards, D.M., et al.: Drugs, 27, 210 (1984)
• Awouters, F. et al., Experientia, 1977, 33, 1657, (pharmacol, rev)
• Ger. Pat., 1977, Janssen, 2 714 437; CA, 88, 50920n, (synth, pharmacol)
• Richards, D.M. et al., Drugs, 1984, 27, 210, (rev, pharmacol)
• Meuldermans, W. et al., Xenobiotica, 1984, 14, 445, (metab)
• Gomez-Parra, V. et al., Monatsh. Chem., 1985, 116, 639, (synth)
• Raves, M.L. et al., Acta Cryst. C, 1992, 48, 1712, (cryst struct)
• Akamatsu, H. et al., Biol. Pharm. Bull., 1993, 16, 568, (pharmacol)
• Paulussen, J.J.C. et al., Arzneim.-Forsch., 1996, 46, 496, (pharmacol, sar)
• Paulussen, J.J.C. et al., Eur. J. Pharmacol., 1996, 312, 121, (pharmacol)
• Martindale, The Extra Pharmacopoeia, 31st edn., Pharmaceutical Press, 1996, 448